### **Overview** Divis Laboratories Ltd (Divi’s) is a globally recognized leader in the Active Pharmaceutical Ingredients (APIs), contract development and manufacturing (CDMO), and nutraceuticals space. With over three decades of operations, the company has established itself as one of the top three global API manufacturers and the world’s largest producer for 10 of its 30 generic APIs. Headquartered in Hyderabad, India, Divi’s serves more than 100 countries, including 12 of the top 20 global pharmaceutical companies. The company operates an **API-exclusive business model**, avoiding competition with customers by not marketing finished dosage forms. This, combined with its strong chemistry expertise, backward integration, regulatory compliance, and sustainable manufacturing practices, has solidified its reputation as a trusted, long-term partner for both generic and innovator pharmaceutical firms. --- ### **Business Segments** Divi’s operations are structured across three core portfolios: 1. **Generic APIs** - Produces 30 high-volume APIs (from tens to thousands of metric tonnes annually), including key molecules like Naproxen, Gabapentin, and Levetiracetam. - Market leader in **10 APIs**, with market shares of 70–75% in select products. - Faces pricing pressure in mature markets but maintains stability through process efficiency and operational excellence. 2. **Custom Synthesis (CDMO)** - Offers full-cycle contract development and manufacturing services for global innovator pharma clients. - Supports molecules across all clinical phases, including multiple **Phase II and III projects**, with two major large-scale projects already in commercial production. - Growing at over **40% YoY**, driven by rising demand for high-complexity APIs, peptides, ADCs, and small molecules. 3. **Nutraceuticals** - Integrated facility at Unit 2 in Visakhapatnam producing carotenoids (Beta Carotene, Lutein, Astaxanthin), lycopene, canthaxanthin, and vitamins (A, D3, E acetate). - Supplies leading global manufacturers of food, dietary supplements, and animal feed. - Certified under **USFDA (CFR 110), Halal, and Kosher** standards. --- ### **Geographic & Revenue Profile** - **Exports:** 88% of total revenue (consistent since 2020), primarily in **USD (86%)**, with EUR (5%) and GBP (9%) exposure. - **Key Markets (2023–24):** - Europe: 52.3% - North America: 17.1% - India: 12.7% - Asia: 13.3% - RoW: 4.6% - Operates in **80 countries**; customers include major pharmaceutical and nutraceutical firms. - **Revenue (FY2024):** ₹80,002 crores (~$9.6 billion, estimated). - **Employees:** ~18,300 (as of Jul 2025). --- ### **Key Capabilities & Technology Investments** #### **Peptide Chemistry** - A strategic focus area with investments in **Solid Phase Peptide Synthesis (SPPS)** and **Liquid Phase Peptide Synthesis (LPPS)**. - Multiple **500-litre reactors** installed, allowing commercial-scale production. - Expanding into **peptide fragments** (e.g., tetramers, decamers) and protected amino acids. - Attracting interest from developers of **GLP-1-based therapies**, with several molecules in commercial and clinical stages. - Full **end-to-end capability** from intermediates to final API, as required by customers. #### **Advanced Manufacturing Technologies** - **Flow Chemistry**: Successfully implemented at pilot scale; commercial rollout planned within 1–2 years. - **Biocatalysis & Green Chemistry**: Embedded across operations to improve yields, reduce waste, and enhance sustainability. - **Atom-to-atom efficiency and solvent recycling** reduce costs and environmental impact. - Proprietary technologies in **iodine recovery** (contrast media) and **photochemistry** (sartans) provide cost and competitive advantages. #### **Backward Integration** - Produces key starting materials (KSMs) and intermediates in-house, including ethylene, propylene, and ortho-tolyl benzonitrile. - Reduces raw material import dependency (now ~46% of consumption) and mitigates supply chain risks. --- ### **Manufacturing Footprint** Divi’s operates **three manufacturing units** across Telangana and Andhra Pradesh: | **Unit** | **Location** | **Key Features** | |--------|-------------|----------------| | **Unit 1** | Choutuppal, Telangana | Est. 1995; includes DTA and DC-SEZ (operational since 2020); hosts peptide and specialty chemistry | | **Unit 2** | Visakhapatnam, AP | Est. 2002; includes Export Oriented Unit, SEZ, DSN SEZ, and DCV SEZ; nutraceuticals and carotenoids | | **Unit 3** | Kakinada, AP | Greenfield, 500-acre site; Phase-I (200 acres) operational Jan 2025; focuses on KSMs, intermediates, and nutraceutical APIs | - **Total Reactor Capacity:** ~16,550 m³ (FY2025), up from ~14,600 m³ in 2023. - Units undergo continuous **upgrades, automation, and modernization** to enhance safety and capacity. --- ### **Kakinada Unit 3 – Strategic Expansion** - **Phase I Investment**: ₹1,200–1,500 crores. - **Commercial Operations**: January 2025. - **Purpose**: Enhances backward integration, frees up capacity in Units 1 & 2 for higher-value custom and generic work. - **Production Scope**: KSMs, intermediates, complex APIs, and nutraceutical APIs. - Regulatory and customer qualification processes underway; commercial ramp-up expected over 1–2 years. --- ### **R&D & Innovation** - **Three R&D Centers**: - Divi’s Research Centre (DRC), Hyderabad - Process Development & Support Centres (PDSCs) at Hyderabad and Visakhapatnam - Staffed by ~700 scientists focused on **green chemistry, process innovation, scale-up, and regulatory compliance**. - **Key Focus Areas**: - Development of processes for off-patent and upcoming generic APIs. - Custom synthesis scale-up (from gram-scale to hundreds of tons in under a year). - Filing of **Drug Master Files (DMFs)** for regulated markets (US, EU). - Holds **dozens of process patents**, reinforcing technological leadership. --- ### **Regulatory & Quality** - Manufacturing facilities approved by **USFDA, EU GMP, Health Canada**, and regulators across **8 jurisdictions**. - ~2,200 employees dedicated to Quality Assurance and Quality Control. - Strong compliance track record: e.g., Unit II cleared a USFDA cGMP inspection with only a single procedural observation. - Zero product recalls in history; trusted partner for proprietary and complex processes. --- ### **Strategic Position in Key Therapeutic Areas** #### **Contrast Media** - Supplies **iodine-based APIs** (CT scans) commercially under long-term contracts. - Gadolinium-based MRI contrast agents in **customer qualification phase**, expected to commercialize by 2026–2027. - **Proprietary iodine recovery system** reduces input costs significantly (iodine price rose from $13 to $80/kg), positioning Divi’s as a low-cost global supplier. #### **Sartans** - Market leader in two sartan APIs; completed qualifications for two others. - Proprietary **photochemistry and recovery technologies** provide a competitive edge. - Full backward integration, including production of **ortho-tolyl benzonitrile** (key starting material). #### **Peptides & GLP-1 Therapeutics** - Strategic focus on **peptide building blocks, fragments, and protected amino acids**. - Clients include developers of **GLP-1, GIP, and GLP-2 analogues**. - Capacity being scaled to serve both commercial and clinical-stage molecules. - Work in **Antibody-Drug Conjugates (ADCs) and nucleotides** in early research phase. --- ### **Market Position & Competitive Edge** - **Six-point strategy** focused on: 1. Upcoming patent expirations (~$20 billion market opportunity, 2023–2025) 2. Sartan leadership 3. Contrast media expansion 4. Peptide capabilities 5. Backward integration 6. Green chemistry & sustainability - **Client Trust**: Maintains >20-year relationships; 100% IP security, on-time delivery, and zero recalls. - **Global Recognition**: Top 10 custom API manufacturer; ranked among top 3 globally for API production. --- ### **Leadership & Governance** - **CEO**: Dr. Kiran S. Divi (Ph.D., Pharmacy), responsible for strategy, manufacturing, QA, and regulatory affairs. - **Whole-time Director**: Mr. Madhusudana Rao Divi (project execution, HSE, plant upgrades). - **Managing Director**: Dr. Murali K. Divi. - **Subsidiaries**: - Divi’s Laboratories (USA) Inc. (nutraceutical marketing) - Divi’s Laboratories Europe AG (Switzerland) – regional presence and customer engagement. ---